Palisade Bio, Inc. (PALI) Key Metrics
PALI valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $245.7M
- Enterprise value
- $148.5M
- P/E (TTM)
- 2.4
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 491.4
- Price / book
- 2.3
- EV / EBITDA
- 0.6
- Dividend yield
- —
- Beta
- 1.62
PALI key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPALI returns How much profit the business earns on the capital it uses.
PALI financial health Debt, liquidity and how easily interest is covered.
PALI efficiency & capital use Working capital cycle and where the cash goes.
PALI valuation history
PALI returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PALI debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PALI cash returned to shareholders
PALI price vs earnings per share
PALI key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $130.8M | — | — | — | — | — | — | — | — | — |
| Enterprise value | −$2.5M | — | — | — | — | — | — | — | — | — |
| Price / book | 1.0 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −12.8% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | −8.3% | — | — | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $2.35 | $1.65 | $8.85 | $78.00 | $975.00 | $3,960.00 | $4,455.00 | $27,900.00 | $154,800.00 | $315,900.00 |
| Per share | ||||||||||
| Revenue per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Earnings per share | −$0.30 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$0.19 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$0.19 | — | — | — | — | — | — | — | — | — |
| Cash per share | $2.40 | — | — | — | — | — | — | — | — | — |
| Book value per share | $2.32 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | $2.32 | — | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Debt per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 55.7M | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −24.5% | −153.6% | −103.4% | −143.7% | — | — | −149.5% | −67.6% | −157.9% | −258.6% |
| Return on invested capital (ROIC) | — | — | — | — | — | — | −243.5% | −609.6% | — | — |
| Return on assets (ROA) | −23.1% | −115.8% | −82.5% | −100.9% | −342.7% | −215.0% | −117.1% | −45.7% | −85.9% | −112.2% |
| Return on tangible assets | −12.5% | −132.7% | −87.5% | −90.5% | −212.7% | −359.4% | −141.2% | −71.2% | −120.5% | −97.5% |
| Financial health | ||||||||||
| Total debt | $71,000 | $169,000 | $369,000 | $404,000 | $199,000 | $1.4M | $288,543 | $5.0M | — | $3.7M |
| Cash & short-term investments | $133.4M | $9.8M | $12.4M | $12.4M | $10.5M | $729,000 | $5.1M | $5.8M | $11.7M | $20.2M |
| Net debt | −$133.3M | −$9.7M | −$12.1M | −$12.0M | −$10.3M | $692,000 | −$4.8M | −$749,110 | −$11.7M | −$16.5M |
| Debt / equity | 0.00 | 0.02 | 0.03 | 0.03 | 0.03 | — | 0.06 | 0.83 | — | 0.33 |
| Debt / assets | 0.00 | 0.02 | 0.03 | 0.03 | 0.02 | 0.47 | 0.04 | 0.66 | — | 0.16 |
| Current ratio | 28.95 | 3.24 | 5.15 | 4.89 | 4.61 | 0.11 | 4.61 | 6.19 | 8.22 | 2.85 |
| Quick ratio | 28.95 | 3.24 | 5.15 | 5.37 | 4.67 | 0.39 | 4.61 | 6.19 | 8.22 | 2.85 |
| Interest coverage | — | — | -871.3 | — | -17.5 | -39.6 | -967.7 | — | -83.1 | -17.7 |
| Working capital | $129.6M | $7.3M | $10.7M | $11.7M | $9.0M | −$7.2M | $4.4M | $5.5M | $10.9M | $13.6M |
| Invested capital | −$3.9M | −$2.2M | −$750,000 | $500,000 | −$2.9M | −$6.4M | $299,619 | $5.3M | −$3.2M | −$5.2M |
| Tangible asset value | $129.4M | $7.5M | $11.3M | $12.5M | $7.4M | −$7.2M | $4.5M | $5.3M | $7.6M | $10.3M |
| Net current asset value | $129.3M | $7.1M | $10.6M | $11.4M | $6.4M | −$9.2M | $4.2M | $4.9M | $7.1M | $9.6M |
| Graham net-net per share | $2.31 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | $99,000 | — | — | — | — | — |
| Share buybacks (net) | $0 | $0 | $0 | — | $99,000 | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | — | — | 1.6% | 4.0% | — | 44.4% | 39.0% | 0.7% | 36.2% | 991.7% |
| Capex / depreciation | 0.00 | 0.00 | 1.00 | 3.33 | 0.00 | 2.00 | 0.04 | 0.01 | 0.33 | 0.48 |
| Stock-based compensation / revenue | — | — | 249.6% | 412.8% | — | 14,896.4% | 21,599.3% | 419.2% | 680.8% | 21,208.5% |
| R&D / revenue | — | — | 2,757.2% | 2,618.8% | — | 22,921.6% | 26,380.4% | 1,523.1% | 3,078.5% | 79,059.5% |
| SG&A / revenue | — | — | 2,482.4% | 3,505.6% | — | 45,843.2% | 47,239.2% | 1,682.1% | 2,215.4% | 49,199.8% |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | 1,157.8 | 1,159.2 | — | 1,080.7 | 4,493.8 | 512.1 | 305.4 | 1,133.3 |
| Days of inventory on hand | — | 1,460.0 | — | -1,735.4 | -2,582.8 | -5,568.9 | — | — | — | — |
| Days payables outstanding | 120,510.8 | 116,313.3 | 112,100.6 | 3,581.2 | 4,405.0 | 4,201.8 | — | -314.8 | — | — |
| Cash conversion cycle (days) | — | — | -110,942.8 | -4,157.3 | — | -8,689.9 | — | 826.9 | — | — |
| Receivables turnover | 0.00 | 0.00 | 0.32 | 0.31 | 0.00 | 0.34 | 0.08 | 0.71 | 1.19 | 0.32 |
| Payables turnover | 0.00 | 0.00 | 0.00 | 0.10 | 0.08 | 0.09 | 0.00 | −1.16 | 0.00 | 0.00 |
| Inventory turnover | — | 0.25 | — | — | — | — | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.00 |
| Average receivables | $144,000 | $86,000 | $793,000 | $794,000 | $104,500 | $40,032 | $189,530 | $364,790 | $217,579 | $50,444 |
| Average payables | $990,500 | $956,000 | $1.2M | $1.6M | $2.0M | $1.7M | $828,485 | $853,814 | $1.6M | $1.9M |
| Average inventory | — | $12,000 | — | −$794,000 | −$1.2M | −$2.2M | — | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 4.9% | 10.2% | 9.9% | 6.4% | 4.4% |
Computed from PALI's annual financial statements (latest annual report filed March 20, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PALI valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 2.4. Palisade Bio earned a return on equity of −24.5% in fiscal 2025. It ended the year with $0.1 million of debt and $133.4 million in cash and short-term investments, a net cash position of $133.3 million.
See the PALI income statement, the PALI chart for price history, or the PALI stock overview for the latest quote and news.
PALI key metrics FAQ
What is Palisade Bio's P/E ratio?
Palisade Bio's trailing P/E ratio is 2.4 based on the last twelve months of earnings (as of October 18, 2026). At the end of fiscal 2025 it was —.
What is Palisade Bio's return on equity?
Palisade Bio's return on equity (ROE) was −24.5% in fiscal 2025: net income of -$16.8 million on average shareholders' equity of $68.4 million.
How much debt does Palisade Bio have?
Palisade Bio had total debt of $0.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Palisade Bio's free cash flow yield?
Palisade Bio generated -$10.8 million of free cash flow in fiscal 2025, a free cash flow yield of −8.3% on its market value at year-end ($130.8 million).
What is Palisade Bio's current ratio?
Palisade Bio's current ratio was 28.95 at the end of fiscal 2025: current assets were 28.95 times current liabilities.